Gregory has made over 1 trades of the Aquestive Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 9,015 units of AQST stock worth $540,900 on 4 December 2019.
The largest trade he's ever made was selling 9,015 units of Aquestive Therapeutics Inc stock on 4 December 2019 worth over $540,900. On average, Gregory trades about 451 units every 0 days since 2016.
You can see the complete history of Gregory Brown stock trades at the bottom of the page.
Dr. Gregory B. Brown M.D. serves as Independent Director of the Company. Dr. Brown is currently Chief Executive Officer of Memgen, LLC, a private development-stage biotechnology company. Dr. Brown is also a co-founder and Vice Chairman at HealthCare Royalty Partners, or HCR Partners, and is a member of that firm’s Senior Advisor Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale University, an M.D. from SUNY Upstate Medical Center and an M.B.A from Harvard University. Dr. Brown currently serves on the boards of the following public pharmaceutical companies: Caladrius Biosciences, Inc. (Nasdaq: CLBS) and Faron Pharmaceuticals Oy (LSN: FARN). Our Board believes that Dr. Brown’s extensive experience in the pharmaceutical industry and investing in life sciences companies, as well as his medical and scientific background, qualifies him to serve on our Board of Directors.
As the Independent Director of Aquestive Therapeutics Inc, the total compensation of Gregory Brown at Aquestive Therapeutics Inc is $97,497. There are 10 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.
Gregory Brown is 66, he's been the Independent Director of Aquestive Therapeutics Inc since 2007. There are no older and 22 younger executives at Aquestive Therapeutics Inc.
Gregory's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker, and Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.
aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include: